Literature DB >> 6128632

Remission induction in acute myeloid leukaemia with oral etoposide.

J P Evans, H G Prentice.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6128632     DOI： 10.1016/s0140-6736(82)91550-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.

Authors:  E Osby; E Liliemark; M Björkholm; J Liliemark
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 2.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

Review 3.  Etoposide and teniposide in the treatment of acute leukemia.

Authors:  M Björkholm
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Authors:  Judith E Karp; Karen Flatten; Eric J Feldman; Jacqueline M Greer; David A Loegering; Rebecca M Ricklis; Lawrence E Morris; Ellen Ritchie; B Douglas Smith; Valerie Ironside; Timothy Talbott; Gail Roboz; Son B Le; Xue Wei Meng; Paula A Schneider; Nga T Dai; Alex A Adjei; Steven D Gore; Mark J Levis; John J Wright; Elizabeth Garrett-Mayer; Scott H Kaufmann
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

5.  Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

Authors:  Judith E Karp; Jeffrey E Lancet
Journal:  Biologics       Date:  2008-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.